- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07942545
Duration of Antibiotic Therapy Evaluation Study in Acute Cholangitis (DATES-AC): An Open-Label, Multicenter, Randomized Non-Inferiority Trial Comparing Short-Course Versus Standard-Course Antibiotic Therapy After ERCP With Early Intravenous-to-oral Switch in Patients With Acute Cholangitis (DATES-AC)
Acute cholangitis is an infection of the bile ducts, usually caused by a blockage that prevents bile from flowing normally. It can lead to serious complications if not treated promptly. Treatment generally includes antibiotics and drainage of the blocked bile duct, usually through a procedure called endoscopic retrograde cholangiopancreatography (ERCP).
Although antibiotics are essential for treating acute cholangitis, the optimal duration of antibiotic treatment after successful bile duct drainage remains uncertain. Current guidelines generally recommend 4 to 7 days of antibiotic treatment. However, shorter treatment may be sufficient after the source of infection has been effectively controlled, potentially reducing unnecessary antibiotic exposure, side effects, hospital stay, and healthcare costs.
The purpose of this study is to determine whether a shorter course of antibiotic treatment (4 days) is as effective as the standard course (7 days) in patients with moderate to severe acute cholangitis who have undergone successful bile duct drainage.
This is a multicenter, randomized, open-label study involving adults aged 19 years or older with moderate to severe acute cholangitis. Patients whose bile duct obstruction has been successfully relieved by ERCP within one day of hospital admission and who meet the study eligibility criteria may participate. Eligible patients will be randomly assigned in a 1:1 ratio to one of two treatment groups.
The short-course group will receive antibiotics for a total of 4 days, while the standard-course group will receive antibiotics for a total of 7 days. In both groups, intravenous antibiotics will initially be given for at least 2 days. Patients who are clinically stable and able to take oral medication will be switched to oral antibiotics as early as possible. Antibiotic selection may be adjusted according to bacterial culture results and antibiotic susceptibility testing. If the initial antibiotics are found to be ineffective, or if the patient's clinical condition requires additional treatment, the antibiotics may be changed or extended to ensure patient safety.
The primary outcome is the clinical cure rate within 14 days after randomization. Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events.
Secondary outcomes include recurrence of cholangitis between days 14 and 30 among patients who initially achieve clinical cure, all-cause mortality within 30 days, total duration of antibiotic use, and patient-reported health status and satisfaction with treatment. The incidence of adverse events within 14 days will also be evaluated. Additional assessments will compare hospital stay and total treatment costs between the two groups.
Participants will be followed up at approximately 14 and 30 days after randomization to assess treatment outcomes, recurrence of infection, additional antibiotic use, and safety.
This study aims to provide evidence on whether a 4-day antibiotic treatment strategy, combined with early conversion from intravenous to oral antibiotics after successful bile duct drainage, can achieve comparable treatment outcomes to the standard 7-day regimen. The findings may help establish a more appropriate antibiotic treatment strategy for patients with acute cholangitis while reducing unnecessary antibiotic exposure and its associated burden.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
- 1. Empirical IV Antibiotics Ceftriaxone + Metronidazole
- 2. Culture-directed IV Antibiotics Ciprofloxacin Piperacillin/Tazobactam Ertapenem Meropenem
- 3. PO Antibiotics Cefpodoxime proxetil Amoxicillin/Clavulanate
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Jaihwan Kim, MD. PhD.
- Numero di telefono: +82-31-787-7075
- Email: drjaihwan@snu.ac.kr
Backup dei contatti dello studio
- Nome: Kwangrok Jung, MD. PhD.
- Email: herojkr@snubh.org
Luoghi di studio
-
-
Gyeonggi-do
-
Ansan, Gyeonggi-do, Corea del Sud, 15355
- Korea University Ansan Hospital
-
Contatto:
- Jong Jin Hyun, MD. PhD.
- Email: sean4h@korea.ac.kr
-
Seongnam-si, Gyeonggi-do, Corea del Sud, 13620
- Seoul National University Bundang Hospital
-
Contatto:
- Jaihwan Kim, MD. PhD.
- Numero di telefono: +82-31-787-7075
- Email: drjaihwan@snu.ac.kr
-
-
Seoul
-
Seoul, Seoul, Corea del Sud, 03080
- Seoul National University Hospital
-
Contatto:
- Woo Hyun Paik, MD. PhD.
- Email: iatrus@snu.ac.kr
-
Seoul, Seoul, Corea del Sud, 07061
- Seoul Metropolitan Government Seoul National University Boramae Medical Center
-
Contatto:
- Dong-Won Ahn, MD. PhD.
- Email: drdwahn@gmail.com
-
Seoul, Seoul, Corea del Sud, 04763
- Hanyang University Medical Center
-
Contatto:
- Jai Hoon Yoon, MD. PhD.
- Email: jaihoonyoon@gmail.com
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Adults aged 19 years or older.
- Patients who voluntarily agree to participate in the study and provide written informed consent after receiving a full explanation of the study.
- Patients who meet the diagnostic criteria for suspected or definite acute cholangitis according to the Tokyo Guidelines 2018 (TG18), regardless of whether the underlying cause is benign or malignant.
- Patients with moderate or severe acute cholangitis according to the TG18 severity grading criteria.
- Patients who have undergone successful biliary drainage by endoscopic retrograde cholangiopancreatography (ERCP) within one calendar day of hospital admission, resulting in relief of biliary obstruction.
Exclusion Criteria:
-
Circulatory failure requiring vasopressor support at the time of ERCP.
-
Persistent or newly developed hypothermia (body temperature below 35°C) between hospital admission and screening.
-
Patients requiring intensive care unit (ICU) treatment.
-
Use of antibiotics within 7 days before hospital admission.
-
Use of systemic antibiotics for 7 days or longer within 90 days before study enrollment for an infection unrelated to the current episode of acute cholangitis.
-
History of recurrent acute cholangitis within the previous 3 months.
-
Complex biliary strictures classified as Bismuth type II or higher.
-
Biliary obstruction of unknown cause.
-
Acute cholangitis caused by dysfunction of a distal biliary stent when the stent was inserted less than 30 days before study enrollment.
-
Complications associated with acute cholangitis present at the time of study enrollment, including acute cholecystitis, acute pancreatitis, liver abscess, or intra-abdominal abscess.
-
Presence of an infection other than acute cholangitis at the time of study enrollment.
-
Patients at high risk of infective endocarditis caused by Gram-positive bacteria, including those with prosthetic heart valves, congenital heart disease, or a previous history of infective endocarditis.
-
Complications following ERCP, including perforation, bleeding, severe post-ERCP pancreatitis, or cardiopulmonary complications related to sedation.
-
Altered upper gastrointestinal anatomy due to previous upper abdominal surgery, except for Billroth I gastrectomy.
-
Immunocompromised patients, including:
- Patients receiving systemic corticosteroids at a dose equivalent to prednisolone 20 mg/day or higher for at least 14 consecutive days.
- Patients who have received cytotoxic chemotherapy, biological agents, or immunosuppressive therapy within the previous 3 months.
- Patients with hematologic malignancies or a history of hematopoietic stem cell transplantation.
- Patients who have undergone solid organ transplantation (liver, kidney, heart, lung, etc.) and are currently receiving immunosuppressive therapy.
- Patients with congenital or primary immunodeficiency disorders.
- Patients with advanced HIV infection, defined as a CD4-positive T-cell count below 200 cells/μL.
-
Pregnant or breastfeeding women.
-
Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: a shorter course of antibiotic treatment
4 days of antibiotics including PO antibioitcs |
Comparision of duration of antibiotics |
|
Comparatore attivo: a standard course of antibiotic treatment
7 days of antibiotics including PO antibioitcs |
Comparision of duration of antibiotics |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
the clinical cure rate within 14 days after randomization
Lasso di tempo: Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)
|
Cure will be assessed based on the resolution of infection-related symptoms and improvement in blood bilirubin levels, defined as a reduction of at least 50% from the initial level or normalization, without predefined treatment failure events. |
Within 14 days after randomization (Day 14; assessment window: Day 11-Day 18)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recurrence rate of acute cholangitis
Lasso di tempo: From Day 14 to Day 30 after randomization
|
Recurrence of cholangitis after cure |
From Day 14 to Day 30 after randomization
|
|
All-cause mortality
Lasso di tempo: Within 30 days after randomization
|
Death regardless of cause |
Within 30 days after randomization
|
|
Patient-reported health status (EQ-5D-5L)
Lasso di tempo: Day 2 and Day 14 after randomization
|
Patient self reports regarding health status |
Day 2 and Day 14 after randomization
|
|
Patient satisfaction with treatment (TSQM-II)
Lasso di tempo: Day 14 after randomization
|
Patient self reports regarding satisfaction with treatment |
Day 14 after randomization
|
|
Total duration of antibiotic use
Lasso di tempo: Within 30 days after randomization
|
Days with antibiotics |
Within 30 days after randomization
|
|
DOOR/RADAR composite outcome
Lasso di tempo: Day 30 after randomization
|
Scoring system regarding the treatment outcomes |
Day 30 after randomization
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hospital stays
Lasso di tempo: Within 30 days after randomization
|
Duration of hospital stay |
Within 30 days after randomization
|
|
Total medical costs
Lasso di tempo: Within 30 days after randomization
|
Total medical costs for the treatment |
Within 30 days after randomization
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Jaihwan Kim, Seoul National University Bundang Hospital
Pubblicazioni e link utili
Pubblicazioni generali
- Gomi H, Solomkin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, Ukai T, Endo I, Iwashita Y, Hibi T, Pitt HA, Matsunaga N, Takamori Y, Umezawa A, Asai K, Suzuki K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Dervenis C, Yokoe M, Kiriyama S, Itoi T, Jagannath P, Garden OJ, Miura F, de Santibanes E, Shikata S, Noguchi Y, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liau KH, Chen MF, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Gimenez ME, Kitano S, Inomata M, Mukai S, Higuchi R, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):3-16. doi: 10.1002/jhbp.518. Epub 2018 Jan 9.
- Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler VG Jr, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Sep 1;61(5):800-6. doi: 10.1093/cid/civ495. Epub 2015 Jun 25.
- Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985 Apr-Jun;4(2):213-26. doi: 10.1002/sim.4780040211.
- Kiriyama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, Hata J, Liau KH, Miura F, Horiguchi A, Liu KH, Su CH, Wada K, Jagannath P, Itoi T, Gouma DJ, Mori Y, Mukai S, Gimenez ME, Huang WS, Kim MH, Okamoto K, Belli G, Dervenis C, Chan ACW, Lau WY, Endo I, Gomi H, Yoshida M, Mayumi T, Baron TH, de Santibanes E, Teoh AYB, Hwang TL, Ker CG, Chen MF, Han HS, Yoon YS, Choi IS, Yoon DS, Higuchi R, Kitano S, Inomata M, Deziel DJ, Jonas E, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):17-30. doi: 10.1002/jhbp.512. Epub 2018 Jan 5.
- Miura F, Okamoto K, Takada T, Strasberg SM, Asbun HJ, Pitt HA, Gomi H, Solomkin JS, Schlossberg D, Han HS, Kim MH, Hwang TL, Chen MF, Huang WS, Kiriyama S, Itoi T, Garden OJ, Liau KH, Horiguchi A, Liu KH, Su CH, Gouma DJ, Belli G, Dervenis C, Jagannath P, Chan ACW, Lau WY, Endo I, Suzuki K, Yoon YS, de Santibanes E, Gimenez ME, Jonas E, Singh H, Honda G, Asai K, Mori Y, Wada K, Higuchi R, Watanabe M, Rikiyama T, Sata N, Kano N, Umezawa A, Mukai S, Tokumura H, Hata J, Kozaka K, Iwashita Y, Hibi T, Yokoe M, Kimura T, Kitano S, Inomata M, Hirata K, Sumiyama Y, Inui K, Yamamoto M. Tokyo Guidelines 2018: initial management of acute biliary infection and flowchart for acute cholangitis. J Hepatobiliary Pancreat Sci. 2018 Jan;25(1):31-40. doi: 10.1002/jhbp.509. Epub 2018 Jan 8.
- Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, Chang PK, O'Neill PJ, Mollen KP, Huston JM, Diaz JJ Jr, Prince JM. The Surgical Infection Society Revised Guidelines on the Management of Intra-Abdominal Infection. Surg Infect (Larchmt). 2017 Jan;18(1):1-76. doi: 10.1089/sur.2016.261.
- Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, Cook CH, O'Neill PJ, Mazuski JE, Askari R, Wilson MA, Napolitano LM, Namias N, Miller PR, Dellinger EP, Watson CM, Coimbra R, Dent DL, Lowry SF, Cocanour CS, West MA, Banton KL, Cheadle WG, Lipsett PA, Guidry CA, Popovsky K; STOP-IT Trial Investigators. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015 May 21;372(21):1996-2005. doi: 10.1056/NEJMoa1411162.
- Pouwels KB, Yin M, Butler CC, Cooper BS, Wordsworth S, Walker AS, Robotham JV. Optimising trial designs to identify appropriate antibiotic treatment durations. BMC Med. 2019 Jun 21;17(1):115. doi: 10.1186/s12916-019-1348-z.
- Masuda S, Imamura Y, Kimura K, Makazu M, Kubota J, Takihara H, Jinushi R, Fujikawa T, Maejima K, Kawanishi A, Yamamoto R, Noda S, Koyama T, Sugitani A, Ryozawa S, Koizumi K. Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). Trials. 2025 Sep 1;26(1):324. doi: 10.1186/s13063-025-09077-1.
- Lee TS, Choi JH, Lee JM, Jeon H, Paik WH, Cho KB, Lee YS, Han JH, Joo JS, Jung MK, Lee J, Ahn DW, Park JM, Kim J, Lee JC, Cho EA, Lee SH. A randomized non-inferiority trial investigating antibiotic adjustments based on blood culture in acute cholangitis. Clin Microbiol Infect. 2025 Jun;31(6):987-994. doi: 10.1016/j.cmi.2024.12.039. Epub 2025 Jan 27.
- Srinu D, Shah J, Jena A, Jearth V, Singh AK, Mandavdhare HS, Sharma V, Irrinki S, Sakaray YR, Gupta R, Gautam V, Rana S, Dutta U. Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial. Am J Gastroenterol. 2024 Jan 1;119(1):176-182. doi: 10.14309/ajg.0000000000002499. Epub 2023 Sep 21.
- Sartelli M, Barie P, Agnoletti V, Al-Hasan MN, Ansaloni L, Biffl W, Buonomo L, Blot S, Cheadle WG, Coimbra R, De Simone B, Duane TM, Fugazzola P, Giamarellou H, Hardcastle TC, Hecker A, Inaba K, Kirkpatrick AW, Labricciosa FM, Leone M, Martin-Loeches I, Maier RV, Marwah S, Maves RC, Mingoli A, Montravers P, Ordonez CA, Palmieri M, Podda M, Rello J, Sawyer RG, Sganga G, Tattevin P, Thapaliya D, Tessier J, Tolonen M, Ulrych J, Vallicelli C, Watkins RR, Catena F, Coccolini F. Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery. World J Emerg Surg. 2024 Jun 8;19(1):22. doi: 10.1186/s13017-024-00552-9.
- Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010 Jan 15;50(2):133-64. doi: 10.1086/649554.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- SNUBH-IMGPB-2026-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .